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ABSTRACT
Pancreatic carcinoma cells lines are known to have a high incidence of
homozygous deletion of the candidate tumor suppressor genepl6 (MTSJ/
CDKN2), which resides in the chromosome 9p21 region. Here we: (a)
examined a seties of these cell lines for the Incidence ofcodeletion of genes
located near p16, in particular, the gene for the enzyme 5'-deoxy-S'-
methylthioadenosine phosphorylase (MTAP) and the genes of the IFN.a
and 43 cluster (IFNs); and (b) investigated whether therapeutic strategies
could be developed that target malignant cells that have undergone the
codeletion of such genes. Five of the eight pancreatic carcinoma cell lines
were plt$@, MTAP was codeleted in all five cases. Because MTAP phos.
phorolyzes 5'-deoxy-S'-methylthioadenosine (MTA), generated as a by
product of polyamine synthesis, to the salvageable purine base adenine,
loss of this pathway in p16W, @f7@4p cells might sensitize these cells to
methotrexate (MTX), the mechanism of action of which involves, in part,
an Inhibition of purine de novo synthesis. MTAP@normal keratinocytes
and pancreatic carcinoma lines had relatively poor sensitivity, In terms of
efficacy, to the purine nucleotide-starving actions of MTX. This may be in
part due to the MTAP-dependent salvage of adenine moieties from endo
genously generated MTA, because the MTAP inhibitor 5'-chloro.S'-de
oxyformycin A potentiates the antipurine actions of MTX in some of these
MTAP@ @jflesAlso, exogenous MTA (10 gEM)reverses the growth-inhibi
tory actions of MTh in these lines. In contrast, MTAP cell lines, which
cannot recycle purines from endogenous MTA, have a relatively high
sensitivity to the antipurine actions of MTX, which is not modulated by
5'-chioro-S'-deoxyformycin A or exogenous MTA. Thus the MTAP loss in
malignant cells may be an example of gene deletion chemoselectivity, in
which genetic deletions that occur as part of the oncogenic process render
these cells more sensitive to particular anticancer agents than normal
cells, which have not undergone such deletions. We also examined whether
the loss of IFN genes sensitize cells to the growth-inhibitory actions of
these cytokines. Three of the five pltS@cell lines bore homozygous dele
tions of IFNAJ and IFNBJ genes, representing each end of the IFN-a41
gene duster; one cell line bore a codeletion ofthe IFNA1 gene but retained
the IFNBJ locus. Whereas the cell lines that were most sensitive to the
growth-inhibitory effects 0fIFN.fi or WN-a2b tended to be those with IFN
deletions, there were enough exceptions to this pattern to indicate that the
IFN genotype does not reliably predict IFN responsiveness.
INTRODUCTION
Loss or inactivation of tumor suppressor genes occurs in many
cancers (1). In some cases, both tumor suppressor gene alleles are lost
by mechanisms involving genetic deletion, i.e. , homozygous deletion.
As result of these events, genes that reside nearby but are otherwise
unrelated to these tumor suppressor genes can frequently be codeleted.
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Loss of these â€œinnocentbystanderâ€•genes may be significant, because
loss of the expression of the proteins encoded by these genes may alter
cellular physiology and, as a consequence, the sensitivity of these
cells to certain therapeutic agents. Because deletion of these innocent
bystander genes occurs in cells undergoing oncogenic transformation
but not in normal cells, it may be possible to design therapeutic
strategies that take advantage of these selective genetic losses.
A potential example of this involves malignant cells that have
undergone genetic deletions in the chromosome 9p2l region. The
genes for two candidate tumor suppressor proteins, pl6'@4 and
pl5@4'@, respectively referred to aspl6 (MTSI/CDK4I/CDKN2) and
p15(MTS2),residecloseto oneanotherin this region(2). Bothof
these proteins act to inhibit the catalytic activity of the cyclin-depend
ent kinase 4 (or 6)-cyclin D complex, which in its active form
phosphorylates the retinoblastoma protein Rb (3, 4); this phosphoryl
ation is thought to be a key step in the progression of cells from a
restriction point late in G1 into S-phase (5). Genetic deletion or
functional inactivation via mutation of one or both of these cyclin
dependent kinase inhibitors might, in principle, contribute to a loss of
the cell's ability to control cell cycle progression, a hallmark of
malignancy (2, 6). Indeed, homozygous deletion or point mutations of
the gene for p16 have been shown to occur in a variety of primary
malignancies (7â€”18).Where studied, the p1.5 gene, which resides
approximately 20 kb centromencally from p16 (2, 12), has been
shown to be codeleted frequently in malignant cells that bear homozy
gous deletions of pitS (8, 9, 12, 14, 15). It has been suggested that
homozygous deletions within the 9p2l region may be relatively
common in particular cancers, because such deletional events could
inactivate pl6, plS, and possibly other tumor suppressor genes resid
ing in this region simultaneously, resulting in a selective growth
advantage (12).
When such deletional events involving multiple loci take place
within the 9p2l region, a number of other neighboring genes can be
lost coincidentally. Examples of this include the gene that encodes the
enzyme MTAP3 (MTAP), which is reported to reside less than 100 kb
from pitS (19), and the IFN gene cluster, consisting of the WN-@3@
gene (IFNBJ) and at least 25 genes and pseudogenes for IFN-a
(IFNA) and IFN-(&)(20), located approximately 500â€”1000kb in the
telomeric direction from p16 (19). MTAP is codeleted with a fre
quency of >85% in cell lines bearing pitS deletions, whereas the IFN
gene cluster is deleted in whole or in part in >50% of p16-deficient
cell lines (21).
Hypothetically, loss of either MTAP or the IFN genes might render
malignant cells with 9p21 defects more sensitive to certain antineo
plastic agents than normal cells that have not undergone these genetic
deletions. MTAP phosphorolyzes the nucleoside MTA, a metabolite
of S-adenosylmethionine produced during the synthesis of the poly
3 The abbreviations used are: MTAP, 5'-deoxy-5'-methylthioadenosine phosphonyl
ase; 5'-CIF, 5'-chloro-5'-deoxyfonmycin A; LU, international unit; KGM, kenatinocyte
growth medium; MTA, 5'-deoxyS'-methylthioadenosine; MTX, methotrexate; MU, 3-(4,5-
dimethylthiazol-2-yl)-2i-diphenyltetnazolium bromide; IC,,, 50% inhibitory concentration.
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amines spermidine and spermine, to yield 5-methylthioribose-l-phos
phate, a methionine precursor, and adenine (22), which is converted to
adenine nucleotides via adenine phosphoribosyltransferase (EC
2.4.2.7; Refs. 23 and 24). Thus, MTAP plays a critical role in
recycling adenine moieties from S-adenosylmethionine, derived orig
inally from AlP, back to adenine nucleotide pools (25). MTAP
deficient malignant cells, unable to metabolize MTA, simply excrete
it (26). Loss of this adenine salvage pathway might sensitize p16@,
MTAP cells to the anticancer agent MTX, the mechanism of action
of which involves, in part, purine nucleotide starvation via an inhibi
tion of punne de novo synthesis (27). Previous work has demonstrated
that one can use exogenous MTA as a purine source to rescue
MTAP-containing malignant cells, but not MTAP-deficient malignant
lines, from the antipurine actions of MTX and related antifolates
(28â€”30).As for the JFNA and JFNB genes, hypothetically, their loss
could render cells more sensitive to the antiproliferative effects of
these cytokines (31). This hypothesis is based on the pharmacological
phenomenon known as â€œsupersensitivity,â€•in which abrogation of the
action of a particular hormone, cytokine, or other chemical signaling
molecule, e.g. , by the action of a receptor antagonist or, in this case,
genetic loss, can lead to a homeostatic up-regulation of the signaling
molecule's receptor levels and/or intracellular signaling machinery
(32).If anup-regulationfproteinsinvolvedwiththecellularsignal
ing response to the IFNs has occurred in p16-deficient malignant cells
that bear codeletions of the IFN cluster, such cells might be particu
larly responsive to the growth-inhibitory actions of IFN-a or -@3.
In this report, we examined a series of human pancreatic carcinoma
cell lines, a high percentage of which been shown to bear deletions or
mutations of pitS (18), for the incidence of codeletion of MTAP, the
genes for IFN-cr and -@3,and other 9p2l markers; we then explored
whether chemotherapeutic approaches involving MTX or the IFNs
could be developed that are strongly active against the malignant cell
types that have lost these loci but less so against normal epithelial
cells (low-passage normal human epidermal keratinocytes were used
in these studies), which have an unmodified 9p2l region.
MATERIALS AND METHODS
Materials. MTA, MTX, thymidine, and human IFN-(3were obtained from
Sigma Chemical Co. (St. Louis, MO); IFN-a2b (Hoffman-LaRoche Inc., Nut
ley, NJ) was obtained from the pharmacy at the University of Massachusetts
Medical Center. 8-'4C-labeled MTA (55 mCi/mmol) was obtained from
Moravek Biochemicals (Brea, CA).
Cell Culture. All pancreaticcarcinomacell lines were obtainedfrom the
American Type Culture Collection (Rockville) and cultured according to
American Type Culture Collection recommendations. Isolation of genomic
DNA and polyadenylated RNA was carried out on â€”0.5â€”2X 10@cells as
described previously (21). Normal human epidermal keratinocytes were ob
mined from Clonetics (San Diego, CA). These cells, obtained at passage 2,
were grown in a serum-free KGM medium consisting of modified MCDB 153
medium supplemented with 0.1 ng/ml epidermal growth factor, 5.0 @.tg/ml
insulin, 0.5 @Wmlhydrocortisone, 0.15 nmt calcium chloride, and 0.03 mg
protein/mi bovine pituitary extract. All drug sensitivity experiments using
keratinocytes were performed on cells from passages 3 on 4.
MTT-based Cell Growth Assay. For studies on the sensitivity of pancre
atic carcinoma cell lines to the antipurine actions of methotrexate (MTX) cell
cultures growing in FCS-containing medium were washed in PBS, harvested
using trypsin-EDTA, and washed twice in the appropriate medium (e.g.,
DMEM) containing 10% horse serum and 20 @Mthymidine. Cells were plated
in this thymidine-containing medium (l-ml final volume) in 12-well dishes
(20,000 cells/well) containing various concentrations of MTX in the presence
or absence of 10 pM MTA (or 25 ,.@M5'-ClF). MTX sensitivity experiments
involving normal epidenmal keratinocytes were performed in thymidine-sup
plemented, serum-free KGM medium in 24-well dishes (6000 cells/well;
0.5-ml final volume). After 7 days in a humidified 37Â°C incubator, 200 @lof
a solution of MiT (5 mg/mI dissolved in PBS) were added directly to each
well, and the plate was incubated an additional 2 h at 37Â°C. A solution of 0.1
N HC1 and 10% Triton X-lOO in isopropanol was added to each well (1.2 ml)
to dissolve the colored metabolite of MTI', formazan. This solubilization was
facilitated by sonicating each well using a Branson 250 sonifier (Danbury,
CT). An aliquot (300 @l)of each well was then transferred to individual wells
in a 96-well plate, and the absorbance at 570 nan was measured in a Molecular
Devices (Sunnyvale, CA) plate reader against a background wavelength of 650
nm. After substraction of background values (wells containing medium but no
cells), the absonbance values were plotted as a percentage of the absorbance
value of control wells, in which cells were grown in the absence of MTX.
Curve fitting and calculation of IC@ values were performed using the lnplot
program (Graphpad, San Diego, CA). Experiments on the sensitivity of the
various cell lines to the growth-inhibitory effects of the IFNs were performed
in a similar manner, except that the experiments were carried out in thymidine
free medium containing 10% FCS instead of horse serum, or serum-free KGM
medium in experiments using normal keratinocytes. Standard curves using
cells from each pancreatic carcinoma line demonstrated that the generation of
formazan from MY!' is linear with cell numbers over a range of 20,000â€”
640,000 cells (up to 1,280,000cells in the case of the Mia PaCa-2 line); in the
case of the normal epidermal keratinocytes, standard curves were linear over
a range of 6,000â€”384,000cells. These standard curves were used to estimate
the number of cell doublings that occurred in the experimental samples.
PCR Analysis of Genomic DNA for 9p21 Markers. Genomic DNA was
purified from each of the various cultured cells (0.5â€”2 X l0@ cells) as
described previously (21). The methods for the PCR-based amplification and
analysis of portions of the p16 gene, including p16 lntlIEx2, p16 Exon 2, and
pitS 3' (alternativelycalled CDK4IIntlfEr2, CDK4IE.ron2, and CDK4I3',
respectively), the IFNAJ and JFNBJ genes, and the D9S171 and D9S169
markers have been detailed (21). The TYRP locus was analyzed by the method
of Fountain et a!. (33). The amplification of a 349-bp segment of exon 2 of the
p15gene(designatedp15Exon2) wascarriedoutusingamodificationofa
procedure described by Washimi et a!. (15). In this case, PCR reaction
mixtures (100 ,.d) contained 0.5 @genomic DNA, 10 mM Tris-HC1 (pH 8.3),
50 mM KC1, 2 mr@tMgCl2, 0.2 misideoxynucleotide triphosphates,2.5 units
AmpliTaq DNA polymerase (Perkin Elmer/Cetus, Norwalk, CT), 5% DMSO,
and 0.4 @LMof each primer (5' primer, 5'-GCICTCTGACCACTCTGCTCT-3';
3' primer, 5'-TGGGCICITGGGAAATTGGGTAAGAA-3').Amplification was
performed in a Perkin Elmer/Cetus 480 DNA thermal cycler under the fol
lowing conditions: 5 mm initial denaturation at 94Â°C,followed by 35 cycles
consisting of a denaturation step of 94Â°C for 45 s, an annealing step of 60Â°C
for 45 s, and an extension step of 72Â°Cfor 1 mm. PCR products were analyzed
using 1.5% agarose gels. The PCR-based genetic deletion results were con
firmed using a reverse transcription PCR technique designed to detect tran
scripts of p16, plS, and the JFNs, as described previously (21).
Assay of MTAP Activity. MTAP activity in cell extracts was examined
using a previously described radioassay, which monitors the conversion of
8-'4C-labeled MTA to 8-'4C-labeled adenine (21). Protein content was deter
mined using the method of Bradford (34). Cell extracts were determined to be
MTAP positive if the activity was greater than 0.01 nmol 8-'4C-labeled
adenine formed/mm/mg protein, and the activity was linear with time (up to
120 mm) and protein content.
RESULTS
Loss of p!6 and the Incidence of Codeletion of Genes and
Markers within the 9p21 Region of Human Pancreatic Carcinoma
Cell Lines. Previous work had demonstrated that the gene encoding
pl6@@4 was deleted or mutated in a high percentage of human
pancreatic cell lines (18); the initial objective of this study was to
determine which other genes or markers residing in the chromosome
9p21 region of these cell lines were codeleted along with this candi
date tumor suppressor gene. Genomic DNA from eight pancreatic
carcinoma cell lines as well as cultures of normal human epidermal
keratinocytes were analyzed by PCR or, in the case of MTAP, a
functional assay, for the presence of a series of nine markers, which
together represent a linkage group of discrete loci across the 9p2l
region. IFNBJ, the most telomenc of these markers, represents the
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p16-deficient cell lines was predicted from previous work, which
suggested that these two genes are codeleted with frequencies exceed
ing 85% (21). Four of the five p16-deficient cell lines displayed a
homozygous deletion of IFNAJ, whereas homozygous deletion of the
IFNBJ gene occurred in three of the five p16-deficient cell lines
(Table 1). There was no apparent relationship between cell doubling
times and the loss of p16, p15, and/or the IFN genes, the protein
products of which, in theory, can act to inhibit cell growth. For
instance, the cell-doubling time of normal epidermal keratinocytes
(26.7 h), which have no deletions of these genes, is not markedly
different than malignant cell lines such as SU.86.86 and Mia PaCa-2,
which lack pl6, pl5, IFNAJ, and IFNBJ (doubling times, 32.6 and
23.9 h, respectively). In the same vein, Capan-1 cells, which lack p16,
p15, and the IFN gene cluster, has a doubling time (55.6 h) that is, in
fact, longer than that of the CFPAC-l line (49.9 h), which bears no
such deletions.
Only one cell line, Capan-l, exhibited deletion of the D9S171
marker, suggesting that this line bears a deletion of at least 5â€”6Mb
within the 9p2l region. None of the cells displayed a loss of the
D9S169 marker, the most centromeric of those examined in this study.
Taken together, these data support two emerging hypotheses concern
ing 9p2l deletions: (a) when 9p2l deletions occur, they include the
p16 locus virtually always; thus, homozygous deletion of any 9p2l
marker is a strong indicator that deletion of p16 has taken place; and
(b) the incidence of codeletion of other 9p2l loci is roughly inversely
proportional to the distance the particular gene maps from p16. For
example, the genes that map most closely to pitS, e.g., p15 and MTAP,
have the highest incidences of codeletion, whereas genes in the 9p21
region that map relatively distantly from p16, e.g., IFNBJ and
D9S171, have proportionately lower incidences of codeletion (21).
MTAP Deletion and Responsiveness to the Antipurine Actions
of MTX. One of our hypotheses is that p16-deficient cells with an
MTAP locus that is also deleted may be more susceptible to the
antipurine actions of antifolates such as MTX than MTAP@ cells,
including normal ones. Part of the mechanism of action of MTX
involves the inhibition of several folate-requiring steps of purine de
novo synthesis, such as glycinamide ribonucleotide transformylase
and 5-amino-4-imidazolecarboxamide ribonucleotide transformylase,
by polyglutamylated forms of MTX and/or dihydrofolate, the latter
accumulating as result of the inhibition of dihydrofolate reductase by
MTX (27, 37, 38). As a consequence, nucleotide pools, including
purines, may be inadequate to support DNA synthesis during S-phase,
Table 1 Homozygousdeletion of 9p2I markers in human pancreatic carcinoma celllinesAll
markers except MTAP were assessed by PCR amplification of genomic DNA, as described in â€œMaterials and Methods.â€• +, the expected PCR product for the particular marker
was observed, demonstrating the presence of at least one copy of the DNA segment in question; â€”, no PCR product was observed, indicating a homozygous deletion. All samples were
assayed at least twice. TYRP is a marker for 9p23(36).Doubling
p16 p16 p15
Cell line time(h) TYRP IFNBJ IFNAJ MTAPâ€• p16 3' Exon2 In:1/Ex2 Exon2 D9S171D9S169Capan-l
55.6 + â€” â€” â€” â€” â€” â€” â€” â€” +
BxPC-3 34.9 + + â€” â€” â€” â€” â€” â€” + +
AsPC-l 37.0 + + + + + +â€œ + + ++(0.46
Â±0.05)
SU.86.86 32.6 + â€” â€” â€” â€” â€” â€” â€” ++Hs7 6T
71.4 + + + + + +c + + ++(1.05
Â±0.29)
PANC-l 31.9 + + + â€” â€” â€” â€” â€” ++CFPAC-l
49.9 + + + + + + + + ++(0.46
Â±0.08)
MiaPaCa-2 23.9 + â€” â€” â€” â€” â€” â€” â€” + +
Normal human epidenmal kenatinocytes 26.7â€• + + + + + + + + + +
(0.45 Â±0.05)a
M'FAP was assessed using the nadiochemical assay described in Ref. 21. Enzyme activity, expressed as nmol ademne formed/mm/mg protein is given in parentheses (mean Â± SD
of at leasttwodeterminations).â€”,the MTAPactivityin thecellextractwas<0.01 nmolademneformed/mm/mgprotein.
b Two-bp deletion (Ref. 18).
C Splice site mutation (Ref. 18).
d @te@n@inedby the suppliers.
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distal end of the IFN cluster and maps â€”1000kb from the p16 locus;
IFNAJ, near the proximal end of the IFN cluster, maps >500 kb from
p16; MTAP maps to a locus <100 kb in the telomeric direction from
p16 (19). The gene encoding pl5'@4 (pJ5IMTS2) resides 15â€”20kb
from p16, in the centromeric direction (2, 12). The microsatellite
marker DS9171 is located at the more centromenc end of the 9p2l
region, at a distance estimated to be 5â€”6Mb from IFNAJ; DS9169 is
believed to reside about 4 centiMorgans closer to the centromere than
D9S171 (35). The TYRP gene, which has been mapped to the 9p23
region (36), was also examined as part of this PCR-based deletional
analysis to control for the presence of chromosome 9 genomic DNA
in each sample.
The results of these deletion studies are presented in Table 1. In this
table, + indicates that the expected PCR product for a particular
marker was observed, signifying that at least one allele of the gene or
marker in question is present in the genomic DNA; â€”indicates that
the PCR product was not observed, indicating a homozygous deletion
of that marker within the genome of that cell line. All of the cell lines
examined were positive for the TYRP locus (Table 1), indicating that
DNA derived from chromosome 9 was present in all the samples.
As shown in Table 1, the Capan-1, BxPC-3, SU86.86, PANC-1,
and Mia PaCa-2 pancreatic carcinoma cell lines were found to have
homozygous deletions of the pitS gene, confirming the results reported
by Caldas et a!. (18). In each case, all three regions of the p16 gene
that were examined, including a 167-bp segment that spans the 3' end
of intron 1 and 20 bp of exon 2 (p16 Intl/Ex2), a 159-bp segment that
lies within exon 2 (p16 Exon 2), and a 355-bp portion of the 3'
noncoding end of exon 3 (p16 3'), were deleted in these cell lines.
Two of the three pancreatic carcinoma cell lines in which p16 is not
deleted, AsPC-l and Hs766T, have been shown to contain mutations
within this gene; thus, of the entire series, only the CFPAC-l line
possesses wild-type p16 (18). As expected, neither p16 nor any of the
9p2 1 markers examined were deleted in low-cell passage (passages 3
and 4), cultured normal human epidermal keratinocytes.
The gene for p15INK4B was codeleted in all five pancreatic carci
noma lines bearing homozygous deletions ofpl6 (Table 1); this result
is similar to those obtained in studies involving gliomas (12), non
small cell lung carcinoma (14, 15), and leukemias (8, 9), in which the
incidences of codeletion of the p15 and p16 genes are very high. In
addition, none of the five cell lines that lack both pitS and p15 had
MTAP activity, indicating that the MTAP locus was also codeleted in
each case (Table 1). The high incidence of the loss of MTAP in
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Fig. 1. Dose-response curves for the antipurine-related, growth-inhibitory effects of MTX (S) or MTX plus 10 @sM TA (0) in MTAP-positive (A ) or MTAP-negative (B) cell lines.
Experimental conditions are described in â€œMaterialsnd Methods.â€•All experiments were earned out in the presence of 20@ thymidine to eliminate the pynmidine-depleting effects
of M1'X. Unless otherwise noted, wells were inoculated with 20,000 cells. Each data point represents the mean Â±SD of four to six independent samples obtained in two on three
experiments. Control (no addition of MTX or MTA) cell doublings: A, epidermal keratinocytes (initial cell number/well, 6,000)4.43; AsPC-l, 4.63; CFPAC-l, 4.20; and Hs766T, 2.16;
B, Mia PaCa-2, 5.93; SU86.86, 3.49; PANC-l, 4.20; and Capan-l, 4.19. Nonlinear regression curve fitting was carried out using the Inplot program.
resulting in cell death (39). The operation of preformed purine salvage
pathways, such as that involving MTAP, might act to relieve, in part,
the purine nucleotide-limiting effects of MTX. Because MTAP-defi
cient cells cannot recycle purine moieties derived from S-adenosyl
methionine during polyamine synthesis, they might be more sensitive
to the purine nucleotide-starving actions of MTX.
To test this, four pl6@, MTAP@ cell lines, including normal epi
dermal keratinocytes, were compared with p16@, MTAP cell lines in
terms of their sensitivity to the antipurine actions of MTX; this was
done by performing dose-response curves with MTX on each cell type
in media containing 20 p.Mthymidine, which negates the suppression
of thymidine nucleotide synthesis effected by MTX. All of these
experiments were performed using media containing horse serum,
which lacks MTAP activity (26). Under these conditions, the antipu
rime-related, growth-inhibitory actions of MIX were relatively weak
in the MTAP@ cell lines; in normal keratinocytes, for example, the
IC50 value was reasonably low, 4.4 Â±2.2 X 108 M,but the efficacy
is poor, with maximal levels of growth inhibition relative to untreated
controls of only 60% being achieved (Fig. 1A, â€¢). In two other
MTAP@ cell lines, Hs7661 and AsPC- 1, both the potency and the
efficacy of the antipurine actions of MIX are low (IC50 values,
5 x lO_6 M;maximal inhibition, 45â€”55%of controls). MIX had a
moderate effect on CFPAC-l cells, with an IC50 of 11.9 Â±3 X lO_8
M and a maximal growth inhibition approaching 90%. In contrast, the
antipurine actions of MIX on the MTAP cells were relatively strong,
with IC50 values of 1.6 Â±0.3, 2.1 Â±0.9, and 11.2 Â±0.8 X l0_8 M
for the relatively fast-growing Mia PaCa-2, SU86.86, and PANC-l
pancreatic carcinoma lines, respectively, and 9.3 X 10_s M for the
slower-growing Capan-1 line, and high efficacies (maximal levels of
growth inhibition, 90% relative to untreated controls in each case;
Fig. lB. â€¢).A fifth MTAP cell line, BxPC-3, also displayed high
sensitivity, in terms of both potency and efficacy, to the antipurine
actions ofMTX (Fig. 2, upper rightpanel). Thus, at least among these
pancreatic cell lines, there seemed to be a difference in the efficacy of
MIX between cells with MTAP@and MTAP genotypes. Coaddition
of 10 @LM IA abrogated the antiproliferative effects of MIX in
MTAP@ normal keratinocytes, Hs7661, and AsPC-l cells almost
completely and effected a partial reversal in CFPAC-l cells (Fig. 1A,
0); thisoccursbecausethesecellsareabletophosphorolyzeMTAto
adenine, thereby relieving the MTX-mediated blockade of purine de
novo synthesis. In marked contrast, exogenous MIA failed to rescue
any of the MTAP cell lines (Fig. lB. 0). To illustrate the selectivity
of this regimen, one can compare the dose-response curves obtained
using MTAP@ keratinocytes with those of MTAP PANC-l cells; at
a MTX concentration of 1 X l0_6 M in the presence of 10 @.LM'FA,
there is an 86% inhibition of the growth of PANC-l cells but only a
14% inhibition for that of the keratinocytes. These results are in
accord with previous work, which showed that MTA can selectively
rescue MTAP@ but not MTAP malignant cells from the antiprolif
erative actions of antifolates (28, 30); here, it is demonstrated that this
strategy can be used to rescue normal epithelial cells selectively, at
least under these specific in vitro conditions.
If, in fact, the functioning of the MIAP-dependent adenine salvage
pathway is the reason for the relatively low antipurine-related actions
of MIX in MTAP@ cells, then an inhibitor of MTAP, by blocking this
adenine salvage mechanism, should potentiate the growth-inhibitory
actions of this antifolate in MTAP@ but not MTAP cell types.
Dose-response curves for the antipurine action of MIX were then
performed on representative cell lines in the absence or presence of 25
@LM5'-ClF, a competitive inhibitor ofMIAP with a K3 value ofO.3 @.aM
(40). At this concentration, which by itself has no effect on the growth
of these cell lines, 5'-ClF caused a leftward shift in the dose-response
curve of MIX in the MTAP@ cell lines; e.g., the IC50 value of the
purine-related antiproliferative actions of MTX is decreased by a
factor of >25-fold in Hs766I cells; a similar shift is observed with
AsPC-l cells (Fig. 2). Also, 5'-ClF produced a small (10â€”20%)but
consistently observed increase in the efficacy of the antipurine-based,
growth-inhibitory actions of MIX in these MTAP@ cell lines. In
contrast, 5'-CIF produces no effect on either the potency or efficacy
of the antipurine actions of MIX in two MIAP-deficient cell lines,
Mia PaCa-2 and BxPC-3, as predicted. Although the MTAP inhibitor
does not increase the efficacy of MIX in MTAP@ cells to the levels
observed in MTAP cell lines, this may be because at this [I]:K@ratio,
a complete blockade of the MIAP reaction is not achieved in intact
cells.4 Overall, the data are consistent with the hypothesis that the
4 T. M. Savarese, unpublished data.
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Fig. 2. Effect of the MTAP inhibitor 5'-CIF on
the growth-inhibitory antipunne actions of MTX in
MTAP-positive (left panels) and -negative (right
panels) cell lines. â€¢,M'I'X alone; 0, MTX in the
presenceof25iLM5'-CIF.Experimentalconditions
are described in â€œMaterialsand Methodsâ€•and the
legend of Fig. 1. Values represent the mean Â±SD
of two to six independent samples. The Inplot pro
gram was used to perform nonlinear regression
curve fitting.
Fig. 3. Dose-response curves for the growth
inhibitory effect of human WN-@ on cell lines of
varying 9p2l genotypes in which the JFNAI and
IFNBI genes are present on deleted. Experimental
conditions are described in â€œMaterialsand Meth
ods.â€•Upper left panel, cell lines with the genotype
pl6@,MTAP, IFNAJ, JFNBJ: Mia PaCa-2
(i@@), control cell doublings, 4.87; Capan-l ( @),
control cell doublings, 6.09; and SU86.86 (0),
control cell doublings, 2.83. Upper righipanel, cell
lines with the genotype pl6@, MTAP, JFNAI,
lFNB1'@:BxPC-3 (9), controlcell doublings,4.93.
Lower leftpanel, cell lines with the genotype pl6@,
MTAP@, IFNA1@, IFNB1@: normal human kenati
nocytes (â€¢),control cell doublings, 5.31; AsPC-l
(0), controlcell doublings,4.87;CFPAC-l(A),
control cell doublings, 5.04; Hs766T (X), control
cell doublings,2.33.Lowerrightpanel,cell lines
with the genotype pl6@, MTAP, IFNA1@,
IFNBJ@ : PANC-l (s), control cell doublings,
4.04. Data points and error bars represent the
mean Â± SD of four to six determinations pen
formed in two or three independent experiments.
Nonlinear regression curve fitting was carried out
using the Inplot program.
Hs766THumanPancreaticCA:p 16â€•, MTAP' MisPaCa-2HumanPancreaticCA:p16 â€¢. MTAPâ€¢
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endogenous recycling of adenine from MTA in part antagonizes the
purine nucleotide-starving actions of MIX.
Loss ofthe LFN Genes and Responsiveness to IFNs. The deletion
of the IFN cluster represents another potentially exploitable difference
between malignant cells with 9p2l defects and normal cells. We
hypothesized that cells that have undergone a complete or partial
deletion of the inteferon cluster might respond to this loss with a
homeostatic up-regulation of IFN-ca and -(3 receptors and/or intracel
lular signaling components, which, in turn, might make the cell
unusually sensitive to the growth-inhibitory actions of IFN-(3 or -a. In
the case of IFN-13, cell lines that bear homozygous deletions of IFN
genes tended to be more responsive, in terms of IC50 values, to this
G.noejpo:plS. LITAP. w@r. IFNBI'
100
Gsnot@ps:p18@,MT@',smAr. IFNB@
50
-C
2
C
00
C
w
2
GsnoOyps:p 16k.5ff@4p IFM4Iâ€¢.IFNB1@
Z1@ j 2 3 4
Gsnotype:plr. MTAP'.IFNAIâ€¢.IFNBI
100
50
C â€˜ â€˜ .
â€”1 0 1 2 3 4
1087
Log[Methotrexate],M
Log [Interferon-@3],mt units/mi
p16. MTAP. AND IFN DELETION AND CHEMOSELECTIVITY
Genotype: p1w, MTAP, IFNAI-, lFNB1@
+
Genotype:p16@, MTAP, IFNAI, IFNBI
100
50
I, â€˜ â€˜ . .
â€”1 0 1 2 3 4 5
Genotype: p1 6@,MTAP@.IFNA1@ !FNB1
Fig. 4. Dose-response curves for the growth
inhibitory effect of human IFN-a2b on cell lines of
varying 9p2l genotypes in which the JFNA I and
IFNBI genes are present on deleted. Experimental
conditions are described in â€œMaterialsand Meth
mis.â€•Upper left panel, cell lines with the genotype
pI6@,MTAP, IFNAI, IFNBI: Mis PaCa-2
(tt), control cell doublings, 5.77; Capan-l (@â€˜),
control cell doublings, 4.01 ; and 5U86.86 (0),
control cell doublings, 2.49. Upper right panel, cell
lines with the genotype p16, MTAP, IFNAI,
IFNB1@:BxPC-3 (9), control cell doublings, 4.81.
Lowerleftpanel, cell lines with the genotype p16k,
MTAP@, JFNA1@, !FNB1@: normal human kerati
nocytes (â€¢),control cell doublings, 5.27; AsPC-l
(0), controlcell doublings,5.77;CFPAC-l(A),
control cell doublings, 4.72; and Hs766T (X), con
trol cell doublings, 2.37. Lower right panel, cell
lines with the genotype pI6, MTAP@,IFNAJ @,
IFNBJ': PANC-l (U), control cell doublings, 3.5.
Data points and enror bars represent the
mean Â± SD of four to six determinations per
formed in two or three independent experiments.
Nonlinear regression curve fitting was carried out
using the Inplot program.
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cytokine than 1FN@ cell lines (Fig. 3). For example, two p16@,
MTAP cell lines in which the IFN gene cluster is codeleted,
Capan-1 and Mia PaCa-2, are relatively sensitive to IFN-f3 (IC50
values, 3 1 Â±9 and 41 Â±3 IU/ml, respectively; Fig. 3, upper left
panel). Also, BxPC-3, which harbors a partial deletion of the IFN
gene cluster (IFNAJ , IFNBJ @)is highly sensitive to the antipro
liferative actions of IFN-/3 (IC50, 6.8 Â±0.7 IU/ml; Fig. 3, upper
right panel). These IC50 values are markedly lower than those of
cell types that are pl6@, MTAP@, IFNA1@, IFNB1@, including
normal keratinocytes, CFPAC-1, AsPC-1, and Hs766I (IC50 val
ues, 305 Â± 26, 934 Â± 110, >4000, and 780 Â± 150 IU/ml,
respectively; Fig. 3, lower left panel) or pl6@, MTAP, IFNA1@,
1FNB1@, i.e., PANC-1 (IC50 value, >4000 IU/ml; Fig. 3, lower
right panel). Contrary to this trend, a third pancreatic carcinoma
line with the pl6@, MTAP, IFNA1 , JFNBJ genotype, 5U86.86,
had a relatively high IC50 value for IFN-@3, 1408 Â±86 IU/ml,
which falls in the range of the IC50 values of IFN@ cells; thus, the
loss of the IFN gene cluster does not necessarily ensure a high
degree of sensitivity to the antiproliferative actions of IFNs.
The responsiveness of individual cell lines to one of the clinically
active forms of IFN-a, IFN-a2b. was also examined (Fig. 4). In
general, the observed IC50 values were considerably higher than those
for WN-@3and did not correlate well with IFN genotype. Taking all the
IFN data together, although some trends were observed, the absence
or presence of these IFN genes was not a reliable predictor of
responsiveness of individual cell lines to the IFNs.
DISCUSSION
In this report, we present evidence that the loss of the gene
encoding MIAP (MTAP), which occurs frequently in conjunction
with the deletion of the putative tumor suppressor genes pitS and
p15 in subsets of malignant cells, renders these cells more sensitive
to the anticancer agent MIX than normal cells, which have
not undergone these deletions, and hence is an example of gene
deletion chemoselectivity. The primary mechanism of loss of
MIAP activity in tumors seems to be homozygous deletion, based
on genetic deletion mapping studies (Table 1; Refs. 19 and 21).
Our original rationale for undertaking this study was that, because
the loss of MTAP would disrupt the pathway by which the adenine
moiety of MTA is recycled back to purine nucleotide pools,
malignant cells lacking this enzyme might be more dependent on
purine de novo biosynthesis and, hence, more sensitive to the
effects of antifolates such as MIX, the action of which involves in
part an inhibition of the purine de novo pathway. It is noteworthy
that some MTAP leukemias have severalfold higher rates of
purine de novo biosynthesis than do MTAP@ leukemias (41).
Indeed, when the antipurine effects of MIX were studied using
media containing thymidine to abrogate the antipyrimidine actions
of MIX, this antifolate was markedly more efficacious against the
five MTAP pancreatic carcinoma lines than against the MTAP@
cell lines, including normal keratinocytes (Figs. 1 and 2). In some
of the MTAP@ cell lines, the purine-related, growth-inhibitory
effect of MIX seemed to plateau (at concentrations in the range of
10_6 M; see Figs. 1 and 2). One can hypothesize that the purine de
novo pathway is inhibited completely at this point, but these cells
are able to survive in part because of efficient recycling of pre
formed purines. However, if operation of the MIAP-dependent
purine salvage pathway was solely responsible for antagonizing the
antipurine actions of MIX, then an MIAP inhibitor ought to
enhance the responsiveness of MTAP@ cells to the antipurine
actions of MIX. A concentration (25 @.aM)of the MTAP inhibitor
5 â€˜-ClF,which by itself does not produce antiproliferative effects,
was found to cause a leftward shift in the dose-response curve of
MIX for several of the MTAP@ pancreatic carcinomas but only
slight increases in the efficacy of MIX. Part of the reason for this
may be the fact that at this concentration, MTAP inhibitors may
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not effect a full blockade of MIAP activity in intact cells,5 but one
also must consider the possibility that MTAP cells undergo other,
as-yet undefined, adaptations to MIAP deficiency, perhaps involv
ing changes in nucleotide and/or folate metabolism, which in some
way sensitizes them to antifolates. For example, it may be relevant
that MIA is a source of formate (42), which can be used readily in
folate metabolism, including the de novo purine pathway; this
formate source would not be available to MTAP cells, perhaps
causing a perturbation of their folate metabolism. Codeletion of
other gene(s) in the 9p2l region, the losses of which sensitize cells
to antifolates, cannot be ruled out at this time. Whatever the precise
mechanism, these finding suggest that the presence of MTAP in
cells predicts a more refractory response to the antipurine actions
of MIX, especially in the higher dose range, and that the loss of
MTAP may be one factor in determining why MIX can be rela
tively tumor selective in some circumstances. Obviously, the ulti
mate test of this in vitro observation would be to determine in
clinical situations whether MTAP tumors are, in fact, more re
sponsive to antifolates with antipurine activity than are MTAP@
tumors. The presence or absence of MTAP within a tumor might be
a crucial parameter in predicting the effectiveness of an antifolate
such as 5,10-dideazatetrahydrofolate, a selective inhibitor of pu
rine de novo synthesis (43), which is currently undergoing clinical
trials (44). The recent isolation ofMTAP cDNA (19) opens the way
for the development of in situ hybridization probes for making
such a determination on tumor samples. Interestingly, a MTAP
non-small cell lung carcinoma cell line has been shown to be
somewhat more sensitive to this antifolate than a MTAP@ line (30).
The hypothesis that endogenous operation of the MTAP-dependent
purine salvage pathway may antagonize the antipurine actions of
MIX is also intriguing from the standpoint of drug development,
because two of the early model systems for screening the activity
of anticancer drugs, the Ll210 and P388 murine leukemias, are
MIAP deficient (45); this may explain, in part, their high degree
of sensitivity to antifolates.
The idea of taking chemotherapeutic advantage of MTAP defi
ciency in subsets of malignant cells was first proposed by Kamatani et
al. in 1981 (28); these investigators demonstrated that one can use
exogenous MIA as a purine source to selectively rescue MIAP
containing cells but not MTAP-deficient cells from the actions of the
purine de novo inhibitors azaserine or MIX (with thymidine coad
ded). However, several difficulties might limit the effectiveness of
this approach in vivo: first, the presence of MTAP in serum (46) might
catalyze the cleavage of MIA to adenine extracellularly, inadvertently
rescuing the MIAP-deficient malignant cell from the antipurine ef
fects of a drug such as MTX. Metabolic cooperativity also might take
place, in which normal, MIAP-positive cells provide purines to the
MIAP-deficient tumor cells, especially when an exogenous purine
source such as MIA is administered. Second, in our experience, MIA
analogues that behave as alternative substrates of MTAP have very
short biological t1,@values (on the order of several minutes; Ref. 47);
thus, there may be pharmacokinetic difficulties in administering MTA
as a rescuing agent. These problems emphasize the importance of the
current findings, which suggest that, at least under defined conditions,
MIX displays more efficacy against MTAP malignant cells than
MTAP@ cells, including normal epithelial cells, even in the absence of
MTA coaddition.
As part of these studies, we asked whether the loss of these IFN
genes might sensitize cells to the antiproliferative actions of these
cytokines, perhaps due to a supersensitivity effect. Whereas the cell
lines that were most sensitive to the growth-inhibitory effects of
IFN-13 or @2btended to be those with IFN deletions, there were
enough exceptions to this trend to warrant the conclusion that the JFN
genotype does not predict responsiveness to the IFNs reliably, at least
in the pancreatic carcinoma cell lines. Similar conclusions were
reached in a study on the sensitivity of glioma cell lines that either
have or lack the 9p2l IFN gene cluster to the growth-inhibitory
actions of IFN-a and -(3 (48). In fact, the biological significance, if
any, of homozygous deletion of the 9p2l IFN gene cluster remains
unclear. To date, we have been unable to correlate the loss of these
genes with changes in doubling times or the ability to respond to the
IFN-inducing, double-stranded RNA species polyinosinic:polycyti
dylic acid (21). One inference that can be made is that the growth
inhibitory actions of these IFNs are not mediated through p16INK4 or
pl5tN@(4@@;if that were the case, pl6@, plS cell lines would have
been uniformly refractory to the IFNs.
One of the general themes presented here is that malignancies of the
same histological type do not necessarily have the same genotype and,
therefore, may not respond to antineoplastic agents in a similar man
ncr. Indeed, of the eight pancreatic carcinoma cell lines in the present
study, five distinct genotypes were identified, and that was based on
analysis of only several markers within the 9p2l region. As discussed
above, those cell types with the MTAP@ genotype predictably re
sponded to MIX differently than did those with the MTAP geno
type. The concept of gene deletion chemoselectivity suggests that by
defining genotypes of a tumor sample, ideally one might be able to
choose a chemotherapeutic regimen directed against the particular
tumor that has a relatively favorable therapeutic index. Whereas these
principles have an appealing logic and can operate under controlled in
vitro conditions, it may not be easy to apply them to practical clinical
situations. Unfavorable drug distribution or pharmacokinetics, meta
bolic cooperativity, low growth fractions, and the tendency to develop
drug resistance, among many other parameters, may limit the effec
tiveness of a particular drug, which, in theory, should display high
selectivity and sensitivity based on the tumor's genotype. Factors such
as these may explain why, although 9p21 deletions involving pitS (and
probably MTAP) are common among primary pancreatic carcinomas
(18) and our data indicate that MIX is especially active against
MTAP pancreatic carcinoma cell lines, antifolates generally do not
produce remissions in this malignancy (49). If analysis of the tumor's
MTAP genotype is to be of any predictive value in the clinic, i.e., to
distinguish potential responders from nonresponders, it would be of
value most probably in cancers in which MIX has proven activity,
e.g., acute lymphoblastic leukemia in children.
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